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Abstract
Background: In obstetrics and gynaecology there has been a rapid growth in the development of new tests and
primary studies of their accuracy. It is imperative that such studies are reported with transparency allowing the
detection of any potential bias that may invalidate the results. The objective of this study was to determine the
quality of reporting in diagnostic test accuracy studies in obstetrics and gynaecology using the Standards for
Reporting of Diagnostic Accuracy - STARD checklist.
Methods: The included studies of ten systematic reviews were assessed for compliance with each of the reporting
criteria. Using appropriate statistical tests we investigated whether there was an improvement in reporting quality
since the introduction of the STARD checklist, whether a correlation existed between study sample size, country of
origin of study and reporting quality.
Results: A total of 300 studies were included (195 for obstetrics, 105 for gynaecology). The overall reporting quality
of included studies to the STARD criteria was poor. Obstetric studies reported adequately > 50% of the time for
62.1% (18/29) of the items while gynaecologic studies did the same 51.7% (15/29). There was a greater mean
compliance with STARD criteria in the included obstetric studies than the gynaecological (p < 0.0001). There was a
positive correlation, in both obstetrics (p < 0.0001) and gynaecology (p = 0.0123), between study sample size and
reporting quality. No correlation between geographical area of publication and compliance with the reporting
criteria could be demonstrated.
Conclusions: The reporting quality of papers in obstetrics and gynaecology is improving. This may be due to
initiatives such as the STARD checklist as well as historical progress in awareness among authors of the need to
accurately report studies. There is however considerable scope for further improvement.
Background
In obstetrics and gynaecology there has been a rapid
growth in the development of new tests and primary
studies of their accuracy. These studies generate a com-
parison of the result from an index test against an
accepted reference standard [1]. The accuracy of the
index test is usually expressed as sensitivity and specifi-
city or other measures like the diagnostic odds ratio
(DOR), likelihood ratio (LR) or area under a receiver-
operator characteristics curve [2]. These allow clinicians
to judge the usefulness and suitability of testing in clini-
cal practice. It is imperative that such studies are
reported with transparency allowing the detection of any
potential bias that may invalidate the results [3-5].
Guidelines for the reporting of other study types have
widely been accepted e.g. CONSORT [6] for randomised
control trials. There has been a format for reporting
evaluations of tests called Standards for Reporting of
Diagnostic Accuracy - STARD [7], introduced in 2003.
The object of the STARD initiative is to improve the
reporting of test accuracy studies to allow for the detec-
tion of potential bias in a study and to make a judge-
ment on the applicability of the index test results. One
of the benefits of using the STARD initiative is to
develop a consistent reporting format across all types of
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lished checklists for diagnostic research. From an initial
75 point check list a consensus meeting formulated a 25
point list that could be employed to accuracy studies.
This list was designed to help readers judge the studies
and to act as a study design tool for authors. Points
were specifically chosen on evidence supporting their
ability to show variations in measures of diagnostic
accuracy [7]. Further supplementing the checklist was
flow diagram which aids the assessment of the study
population, the recruitment method and indicates the
numbers receiving the index test, those excluded and
those compared with the reference standard at different
stages of the study. STARD should allow a reader to cri-
tically appraise the study design, analysis and results.
Previous studies have looked at the impact of STARD
in specific clinical areas [8-12] with varying outcomes
and the overall quality of reporting of studies which was
generally found to be poor. Smidt et al studied reporting
quality pre and post STARD in twelve general medical
journals and found the mean number of STARD items
reported pre-STARD publication was 11.9 (3.5-19.5) and
post-publication was 13.6 (4.0-21.0). Coppus et al found
that the mean compliance for articles published in Ferti-
lity and Sterility and Human Reproduction was 12.1
(6.5-20). There is no published research looking at the
impact of STARD in obstetrics.
This study aims to assess the reporting quality of test
accuracy studies in obstetrics and gynaecology and the
impact of the STARD statement and compare the qual-
ity between the two specialities.
Methods
We developed a protocol to assess the impact of
STARD on studies included in ten systematic reviews
performed over the period 2004-2007. The studies cov-
ered the time period 1977-2007. We included reviews of
minimal and non invasive tests to determine the lymph
node status in gynaecological cancers [13-15] and
reviews of Down’s serum screening markers and uterine
artery Doppler to predict small for gestational age in
obstetrics [16,17]. These systematic reviews were
selected as they were all performed by the authors
according to prospective protocols and recommended
methodology with prospective assessment of reporting
quality using the STARD checklist thus uniform assess-
ment could be ensured. The STARD checklist was
applied to each of the studies included in all the reviews
with the reporting item being determined as either pre-
sent, absent, unclear or not applicable (additional file 1).
All studies were assessed by TJS and RKM in duplicate,
where there was disagreement consensus was achieved
following assessment by a third reviewer (KSK). In the
event that several tests had been applied to the same
patient, the results including the largest number of
patients were used in this study or where there was no
difference, one index test was selected at random, this
ensured patients were only included once.
We addressed the following questions: Has the intro-
duction of STARD improved reporting quality?; does
study size correlate with reporting quality?; is there a
geographical pattern to reporting quality? The percentage
compliance of studies with STARD items was compared
between both specialties before and after the introduc-
tion of STARD and over time using the unpaired t test
to assess the effect of STARD on the reporting quality
of studies. With the publication of STARD in 2003
the assumption was made that all studies published
pre 2004 were published without the benefit of this
directive.
We examined the relationship between sample size
and compliance with STARD using Spearman’sr a n k
correlation coefficient (Rho). Kruskal Wallis was used to
investigate any relationship between geographical distri-
bution and reporting quality. The country of origin of a
study was determined by the country of the correspond-
ing author. Where a significant result was found, pair-
ways comparison was made using Conover Inman
procedure. Countries were grouped depending on the
number of articles published and the mean journal
impact factor and adjusted for gross domestic product
and population, based on previous publication [18].
Where there was a large disparity in number of studies
per geographical area, some studies were re grouped to
avoid large differences in group size and potentially
spurious results. For obstetric reviews geographical areas
were Oceania, USA, Canada, Asia, Japan, Africa, Eastern
Europe and Western Europe and for gynaecology studies
there were no studies from Oceania or Canada, but
Latin America was added.
In the initial analysis those reporting items coded as
unclear and not applicable were excluded. For all of the
above analysis, due to the uncertainty of whether report-
ing items coded as unclear represented methodological
failure, sensitivity analysis was performed excluding this
code and adding it to the not reported group for all
comparisons. Similarly sensitivity analysis was also per-
formed to assess the effect of those items assessed as
not applicable, with their initially exclusion to the analy-
sis and then addition as if they were reported so as not
to penalise studies which had a larger number of not
applicable items and would therefore potentially have a
seemingly lower compliance with STARD.
Results
A total of 300 studies (195 obstetric and 105 gynaecolo-
gical studies) were identified and included in this analy-
sis. 82% (160/195) of the obstetric and 83.8% (88/105)
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STARD initiative. The overall percentage compliance
with individual reporting items and percentage compli-
ance pre- and post-STARD publication is shown in
table 1 for gynaecology and table 2 for obstetrics. The
included obstetric studies reported adequately > 50% of
the time for 62.1% (18/ 29) of the items as assessed in
this review and for gynaecology 51.7% (15/29). Items
where reporting was uniformly poor (both obstetrics
and gynaecology studies < 50%) were participant sam-
pling, description of technique of reference standard,
description of expertise of people performing index and
Table 1 Percentage compliance with individual STARD criteria for included diagnostic accuracy studies in gynaecology
STARD
Item
Description Percentage compliance
overall gynaecology (%)
N = 105
Percentage
compliance pre
2004 (%)
N=8 5
Percentage
compliance post
2004 (%)
N=1 7
Difference
% (95% CI)
S1 Article is identified as study of
diagnostic accuracy
64.8% 64.8% 64.7% -0.1% (-25%; 25%)
S2 States research question or aims 63.6% 63.6% 64.7% 1.1% (-24%; 26%)
S3 Describes study population 77.3% 77.3% 64.7% -12.6% (-35%; 10%)
S4 Describes participant recruitment 35.2% 35.2% 94.1% 58.9% (33%; 85%)
S5 Describes participant sampling 40.9% 40.9% 64.7% 23.8% (-2%; 50%)
S6 Describes index standard 83.0% 83.0% 88.2% 5.3% (-14%; 24%)
S7 Describes reference standard 30.7% 30.7% 76.5% 45.8% (21%; 71%)
S8a Describes technique of index test 50.0% 50.0% 82.4% 32.4% (7%; 58%)
S8b Describes technique of reference
standard
30.7% 30.7% 70.6% 39.9% (15%; 65%)
S9a Describes cut-off for index test 96.6% 96.6% 70.6% -26.0% (-40%; -12%)
S9b Describes cut-off for reference
standard
0.0% 0.0% 0.0% 0.0% (0%; 0%)
S10a Describes persons executing index
test
3.4% 3.4% 5.9% 2.5% (-7%; 12%)
S10b Describes persons executing
reference standard
0.0% 0.0% 0.0% 0%
S11a Were results of index test blinded? 22.7% 22.7% 0.0% -22.7% (-43%; -2%)
S11b Were results of reference test
blinded?
20.5% 20.5% 11.8% -8.7% (-29%; 12%)
S12 Describes methods for statistics used 30.7% 30.7% 0.0% -30.7% (-53%; -8%)
S13 Describes methods for calculating
test reproducibility
0.0% 0.0% 0.0% 0%
S14 Reports dates of study 86.4% 86.4% 94.1% 7.8% (-9%; 25%)
S15 Reports characteristics of study
population
10.2% 10.2% 11.8% 1.5% (-14%; 17%)
S16 Reports number of eligible patients
that did not undergo either test
34.1% 34.1% 41.2% 7.1% (-18%; 32%)
S17 Time interval between tests and any
treatment
70.5% 70.5% 94.1% 23.7% (1%; 46%)
S18 Reports distribution of severity of
disease
75.0% 75.0% 94.1% 19.1% (-2%; 41%)
S19 Reports cross tabulation of results 42.0% 42.0% 29.4% -12.6% (-38%; 13%)
S20 Reports adverse events 15.9% 15.9% 17.6% 1.7% (-17%; 21%)
S21 Reports estimates of diagnostic
accuracy
62.5% 62.5% 41.2% -21.3% (-47%; 4%)
S22 Reports how missing results were
handled
21.6% 21.6% 35.3% 13.7% (-8%; 36%)
S23 Reports estimates of variability of
accuracy
0.0% 0.0% 0.0% 0%
S24 Reports estimates of test
reproducibility
0.0% 0.0% 0.0% 0%
S25 Discuss clinical applicability of
findings
100.0% 100.0% 100.0% 0%
* 100% not applicable.
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those interpreting reference standard, assessment of test
reproducibility, tabulation of results and description of
adverse events.
There was a greater compliance with STARD for
obstetric than gynaecological studies (p = < 0.0001).
There was significant improvement in the reporting
quality of obstetric studies after the introduction
of STARD (p = 0.0004). Two studies in obstetrics used
a STARD flow diagram following the publication of
STARD. Although there was an improvement in the
mean compliance in gynaecological studies as well, this
did not reach significance (p = 0.08). Tables 1 and 2
also demonstrate the mean differences in percentage
Table 2 Percentage compliance with individual STARD criteria for included diagnostic accuracy studies in obstetrics
STARD
Item
Description Percentage compliance
overall obstetrics (%)
N = 105
Percentage
compliance pre
2004 (%)
N=8 5
Percentage
compliance post
2004 (%)
N=1 7
Difference
% (95% CI)
S1 Article is identified as study of
diagnostic accuracy
27.2 19.4% 62.9% 43.5% (27%; 60%)
S2 States research question or aims 94.9 93.8% 100.0% 6.3% (-2%; 14%)
S3 Describes study population 74.4 72.5% 82.9% 10.4% (-6%; 26%)
S4 Describes participant recruitment 85.1 83.8% 91.4% 7.7% (-5%; 21%)
S5 Describes participant sampling 36.4 33.1% 51.4% 18.3% (1%; 36%)
S6 Describes index standard 59.5 58.8% 62.9% 4.1% (-14%; 22%)
S7 Describes reference standard 86.7 85.0% 94.3% 9.3% (-3%; 22%)
S8a Describes technique of index test 45.1 45.0% 45.7% 0.7% (-17%; 19%)
S8b Describes technique of reference
standard
0 0.0% 0.0% 0%
S9a Describes cut-off for index test 96.9 96.3% 100.0% 3.8% (-3%; 10%)
S9b Describes cut-off for reference
standard
75.9 75.0% 80.0% 5.0% (-11%; 21%)
S10a Describes persons executing index
test
8.2 9.4% 2.9% -6.5% (-17%; 4%)
S10b Describes persons executing reference
standard
0 0.0% 0.0% 0%
S11a Were results of index test blinded? 100 100.0% 100.0% 0%
S11b Were results of reference test blinded? 8.2 6.3% 17.1% 10.9% (1%; 21%)
S12 Describes methods for statistics used 53.3 48.1% 77.1% 29.0% (11%; 47%)
S13 Describes methods for calculating test
reproducibility
12.3 13.8% 5.7% -8.0% (-20%; 4%)
S14 Reports dates of study 65.1 63.1% 74.3% 11.2% (-6%; 29%)
S15 Reports characteristics of study
population
67.2 61.3% 94.3% 33.0% (16%; 50%)
S16 Reports number of eligible patients
that did not undergo either test
69.2 69.4% 71.4% 2.1% (-15%; 19%)
S17 Time interval between tests and any
treatment
11.8 10.0% 20.0% 10.0% (-2%; 22%)
S18 Reports distribution of severity of
disease
86.7 83.8% 100.0% 16.3% (4%; 29%)
S19 Reports cross tabulation of results 49.2 48.8% 51.4% 2.7% (-16%; 21%)
S20 Reports adverse events 0* 0.0% 0.0% 0%
S21 Reports estimates of diagnostic
accuracy
54.4 50.0% 74.3% 24.3% (6%; 43%)
S22 Reports how missing results were
handled
63.6 63.1% 65.7% 2.6% (-15%; 20%)
S23 Reports estimates of variability of
accuracy
56.4 50.6% 82.9% 32.2% (14%; 50%)
S24 Reports estimates of test
reproducibility
12.8 14.4% 5.7% -8.7% (-21%; 4%)
S25 Discuss clinical applicability of findings 99.5 100.0% 97.1% -2.9% (-5%; 0%)
* 100% not applicable.
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shows the trend in compliance with the STARD criteria
over time. Analysis of the correlation between sample
size and compliance with STARD revealed a positive
correlation in both obstetrics (Rho = 0.37, p = < 0.0001)
and gynaecology (Rho = 0.24, p = 0.0123). Investigation
in to the relationship between geographical area of pub-
lication and the compliance with STARD showed no
relationship for obstetrics or gynaecology, (Kruskal-
Wallis 5.05 p = 0.65 and 6.79 p = 0.24 for obstetrics
and gynaecology respectively) table 3. Sensitivity analysis
showed no significant difference in any of the results.
Discussion
The reporting of included studies in this review overall
was poor with obstetric studies demonstrating better
reporting than the gynaecological studies. In both spe-
cialties the geographical origin had no effect on the
reporting quality; however the study size showed a
positive correlation. There has been a trend in improve-
ment in reporting quality, more so in obstetrics than
gynaecology, however there is still significant room for
improvement.
There was poor compliance with STARD in many of
the studies in this review, in many studies it was unclear
whether the study complied with the reporting item.
This lack of clarity could potentially affect our infer-
ences, but in other fields it is well known that unclear
reporting is associated with bias [19]. Although the stu-
dies crossed both obstetrics and gynaecology they were
limited to a subset of conditions within these fields. It is
likely that these results can be translated across obste-
trics and gynaecology, however care should be taken as
to the generalisability of this study.
We compared our results to those from similar studies
in other subject areas. Within reproductive medicine the
reporting of individual items still showed wide variation
post STARD publication
8. In medical journals there was
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Figure 1 Bar chart showing mean percentage compliance of studies with STARD criteria, line shows trend over time.
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lating test reproducibility, distribution of severity of dis-
ease, variability in accuracy between subgroups and use
of a flow diagram
9. In obstetrics and gynaecology there
was an improvement in describing participant sampling/
recruitment, description/blinding of reference standard,
reporting the characteristics of the study population,
distribution of severity of disease and variability of accu-
racy. There was no significant improvement in the use
of a flow diagram. In gynaecology however, there were
s o m ei t e m st h a ts h o w e dp o o r e rr e p o r t i n gp o s tS T A R D
such as description of cut-off of index test and blinding.
There are thus no particular items of the STARD check-
list that have been poorly adopted or interpreted by
authors more that authors have been slow to adopt the
STARD checklist and with its publication still being
very recent. As more journals adopt the STARD state-
ment and more authors make use of it at the planning
and data collection stage of their research there will
hopefully be a considerable improvement in the report-
ing quality in all subject areas in the future.
Poor reporting of a study does not necessarily corre-
late with bad quality. Accurate reporting is necessary to
allow transparency of a study and to ensure the results
are interpreted correctly. The application of the STARD
checklist may help prevent the implementation of unne-
cessary or inaccurate tests which can lead to unneces-
sary financial expenditure and potentially serious
consequences for patients.
Conclusion
The reporting quality of papers in obstetrics and gynae-
cology is improving. This may be due to initiatives such
as the STARD checklist as well as historical progress in
awareness among authors of the need to accurately
report studies. There is however considerable scope for
further improvement.
Additional material
Additional file 1: STARD checklist. This file contains the Standards for
Reporting of Diagnostic Accuracy checklist and a description of each of
the checklist items.
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